mPRδ Inhibitors

Chemical inhibitors of mPRδ include a spectrum of compounds that primarily function as antagonists to the progesterone receptor, to which mPRδ belongs. Progesterone, the natural ligand, normally activates mPRδ; however, the presence of synthetic antagonists such as RU486 (Mifepristone) and Onapristone can prevent this activation. These chemicals exert their inhibitory effect by binding to the ligand-binding domain of mPRδ, thereby obstructing the interaction between the receptor and its endogenous progesterone ligand. Similarly, Telapristone and Tanaproget, through their anti-progestin activity, bind to mPRδ in a manner that does not activate the receptor, effectively inhibiting the action that would otherwise be stimulated by progesterone.

Furthermore, Lilopristone, Aglepristone, and Ulipristal achieve inhibition of mPRδ by serving as competitive antagonists, ensuring that the natural hormone does not engage with the receptor. This competition at the receptor site is a common mechanism by which these chemicals enforce inhibition. Asoprisnil and Lonaprisan also inhibit mPRδ by selectively binding to the receptor, disabling its ability to initiate downstream signaling that would result in activation. Vilaprisan operates under a similar antagonistic principle, blocking the receptor from being activated by natural ligands. Each of these chemicals, by binding to or affecting the receptor in specific ways, ensures that mPRδ remains in an inactive state, unable to fulfill its role in response to progesterone binding.